Help | Scores |Exit
Fragmin | Magnex | Solu Medrol
Streptomycin Drug Name:  
A|B|C|D|E|F|G|H|I|K|L|M|N|O|P|Q|R|S|T|V|Z
Quick Dosage
Indications
Dosages
Interactions
Precautions
Contraindications
Adverse Reactions
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interactions:

Amoxycillin

  • Adverse Effect: Loss of Streptomycin efficacy  
  • Clinical Management: Monitor patients for Streptomycin effectiveness.

    Ampicillin

  • Adverse Effect: Loss of Streptomycin efficacy  
  • Clinical Management: Monitor patients for Streptomycin effectiveness.

    Atracurium

  • Adverse Effect: enhanced and/or prolonged neuromuscular blockade which may lead to respiratory depression and paralysis  
  • Clinical Management: Avoid concomitant use of Streptomycin and Atracurium if possible. Concurrent use of Streptomycin and Atracurium requires close monitoring of the patients clinical condition, especially respiratory and oxygenation status.

    Bacampicillin

  • Adverse Effect: Loss of Streptomycin efficacy  
  • Clinical Management: Monitor patients for Streptomycin effectiveness.

    Benzathine Penicillin

  • Adverse Effect: Loss of Streptomycin efficacy  
  • Clinical Management: Monitor patients for Streptomycin effectiveness.

    Benzyl Penicillin

  • Adverse Effect: Loss of Streptomycin efficacy  
  • Clinical Management: Monitor patients for Streptomycin effectiveness.

    Bumetanide

  • Adverse Effect: An increased risk of ototoxicity (tinnitus, transient or permanent hearing loss, dizziness, vertigo)  
  • Clinical Management: Avoid using this combination in patients with renal impairment, inner ear dysfunction, and those receiving high doses of either drug. If possible, avoid giving long courses of this combination therapy. Before beginning treatment, determine that hearing and renal function are unimpaired and follow up with regular audiometric and renal function monitoring. Alternatively, consider switching to a non-loop diuretic or use of an antibiotic not associated with ototoxicity.

    Capreomycin

  • Adverse Effect: streptomycin toxicity (ototoxicity, nephrotoxicity)  
  • Clinical Management: If concomitant administration is necessary, respiratory function, renal function and auditory function should be monitored closely.

    Carbenicillin

  • Adverse Effect: Loss of Streptomycin efficacy  
  • Clinical Management: Monitor patients for Streptomycin effectiveness.

    Carboplatin

  • Adverse Effect: ototoxicity  
  • Clinical Management: If clinically acceptable, an alternate antibiotic (a non-aminoglycoside) may be preferred.

    Cefaclor

  • Adverse Effect: an increased risk of nephrotoxicity  
  • Clinical Management: Coadministration of Streptomycin with Cefaclor could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.

    Cefadroxil

  • Adverse Effect: an increased risk of nephrotoxicity  
  • Clinical Management: Coadministration of Streptomycin with Cefadroxil could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.

    Cefazolin

  • Adverse Effect: an increased risk of nephrotoxicity  
  • Clinical Management: Coadministration of Streptomycin with Cefazolin could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.

    Cefixime

  • Adverse Effect: an increased risk of nephrotoxicity  
  • Clinical Management: Coadministration of Streptomycin with Cefixime could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.

    Cefoperazone

  • Adverse Effect: an increased risk of nephrotoxicity  
  • Clinical Management: Coadministration of Streptomycin with Cefoperazone could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.

    Cefotaxime

  • Adverse Effect: an increased risk of nephrotoxicity  
  • Clinical Management: Coadministration of Streptomycin with Cefotaxime could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.

    Cefpodoxime

  • Adverse Effect: an increased risk of nephrotoxicity  
  • Clinical Management: Coadministration of Streptomycin with Cefpodoxime could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.

    Ceftazidime

  • Adverse Effect: an increased risk of nephrotoxicity  
  • Clinical Management: Coadministration of Streptomycin with Ceftazidime could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.

    Ceftizoxime

  • Adverse Effect: an increased risk of nephrotoxicity  
  • Clinical Management: Coadministration of Streptomycin with Ceftizoxime could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.

    Ceftriaxone

  • Adverse Effect: an increased risk of nephrotoxicity  
  • Clinical Management: Coadministration of Streptomycin with Ceftriaxone could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.

    Cefuroxime

  • Adverse Effect: an increased risk of nephrotoxicity  
  • Clinical Management: Coadministration of Streptomycin with Cefuroxime could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.

    Cephalexin

  • Adverse Effect: an increased risk of nephrotoxicity  
  • Clinical Management: Coadministration of Streptomycin with Cephalexin could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.

    Cephaloridine

  • Adverse Effect: an increased risk of nephrotoxicity  
  • Clinical Management: Coadministration of Streptomycin with Cephaloridine could produce additive nephrotoxic effects. Use of these agents should be avoided in patients with prior renal insufficiency. If coadministration of these two antibiotic classes is necessary, patients should be monitored for evidence of nephrotoxicity.

    Cloxacillin

  • Adverse Effect: Loss of Streptomycin efficacy  
  • Clinical Management: Monitor patients for Streptomycin effectiveness.

    Frusemide

  • Adverse Effect: ototoxicity and/or nephrotoxicity  
  • Clinical Management: Consider periodic auditory testing for patients on high doses of either drug. Also monitor renal function.

    Mg. salts

  • Adverse Effect: Neuromuscular weakness  
  • Clinical Management: Monitor patients for respiratory dysfunction and apnea. If neuromuscular blockade occurs, discontinue Streptomycin and change antibiotic therapy. Patients receiving large cumulative doses of aminoglycosides should have serum calcium, magnesium, potassium, and creatinine monitored.

    Pancuronium

  • Adverse Effect: enhanced and/or prolonged neuromuscular blockade which may lead to respiratory depression and paralysis  
  • Clinical Management: Avoid concomitant use of Streptomycin and Pancuronium if possible. Concurrent use of Pancuronium and Streptomycin requires close monitoring of the patients clinical condition, especially respiratory and oxygenation status.

    Penicillin V ( Phenoxymethyl )

  • Adverse Effect: Loss of Streptomycin efficacy  
  • Clinical Management: Monitor patients for Streptomycin effectiveness.

    Pipecuronium

  • Adverse Effect: enhanced and/or prolonged neuromuscular blockade which may lead to respiratory depression and paralysis
  • Clinical Management: Avoid concomitant use of Streptomycin and Pipecuronium if possible. Concurrent use of Streptomycin and Pipecuronium requires close monitoring of the patients clinical condition, especially respiratory and oxygenation status.

    Piperacillin

  • Adverse Effect: Loss of Streptomycin efficacy  
  • Clinical Management: Monitor patients for Streptomycin effectiveness.

    Procaine Penicillin

  • Adverse Effect: Loss of Streptomycin efficacy  
  • Clinical Management: Monitor patients for Streptomycin effectiveness.

    Succinyl Choline

  • Adverse Effect: succinylcholine toxicity (respiratory depression)  
  • Clinical Management: Titrate the dose of the Succinyl Choline carefully. Monitor patients not on a ventilator for respiratory paralysis.

    Vecuronium

  • Adverse Effect: enhanced and/or prolonged neuromuscular blockade which may lead to respiratory depression and paralysis  
  • Clinical Management: Avoid concomitant use of Streptomycin and Vecuronium if possible. Concurrent use of Streptomycin and Vecuronium requires close monitoring of the patients clinical condition, especially respiratory and oxygenation status.
  • Salmeterol Xinafoate
    Silver Nitrate
    Sodium Bicarbonate
    Sodium Fluoride
    Sodium Phosphates
    Somatropin
    Spironolactone
    Stavudine
    Streptomycin Sulfate
    Sulfacetamide Sodium
    Sulfasalazine
    Sulfisoxazole
    Saccharine
    Saccharomyces
    Salbutamole
    Salbutamole - inh
    Salicylates
    Salmeterol - inh
    Satranidazole
    Sacnidazole
    Selegiline
    Senna
    Serratiopeptidase
    Sertraline
    Sibutramine
    Sildenafil citrate
    Silver Sulfadiazine - Ocular
    Silver Sulphadiazine
    Silymarin
    Simvastatin
    Sisomicin
    Sisomicin - Ocular
    Snake Venom Antisera
    Sod Picosulphate
    Sodium Antimony Gluconate
    Sodium Cromoglycate
    Sodium Cromoglycate - Inh
    Sodium Cromoglycate - Ocular
    Sodium Fusidate
    Sodium Hyaluronate
    Sodium Nitroprusside
    Sodium Valproate
    Sodium tetradecyl
    Soframycin - Ocular
    Somatostatin
    Sotalol
    Sparfloxacin
    Spectinomycin
    Spiramycin
    Stanozolol
    Streptokinase
    Streptomycin
    Succinyl Choline
    Sucralfate
    Sulbutiamine
    Sulfonamide - VU
    Sulphacetamide - Ocular
    Sulphadiazine
    Sulphamethizole
    Sulphasalazine-Antisecr
    Sumatriptan
     
    Disclaimer